Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Number of items: 19.

Love, Sharon B., Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca, Hague, Dominic, Townsend, Stephen, Amos, Claire, South, Annabelle, Sturgeon, Kate, Langley, Ruth, Maughan, Timothy, James, Nicholas, Hall, Emma, Kernaghan, Sarah, Bliss, Judith, Turner, Nick, Tutt, Andrew, Yap, Christina, Firth, Charlotte, Kong, Anthony, Mehanna, Hisham, Watts, Colin, Hills, Robert, Thomas, Ian, Copland, Mhairi, Bell, Sue, Sebag-Montefiore, David, Jones, Robert, Parmar, Mahesh K B and Sydes, Matthew R 2022. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials 23 , 757. 10.1186/s13063-022-06680-4
file

Loo, Sun, Dillon, Richard, Ivey, Adam, Anstee, Natasha S, Othman, Jad, Tiong, Ing Soo, Potter, Nicola, Jovanovic, Jelena, Runglall, Manohursingh, Chua, Chong Chyn, Bajel, Ashish, Ritchie, David, Gray, Kelli, Yeoh, Zhi Han, McBean, Michelle, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Russell, Nigel H and Wei, Andrew H. 2022. Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome. Blood 10.1182/blood.2022016567
Item availability restricted.
file

Tazi, Yanis, Arango-Ossa, Juan E., Zhou, Yangyu, Bernard, Elsa, Thomas, Ian, Gilkes, Amanda, Freeman, Sylvie, Pradat, Yoann, Johnson, Sean J., Hills, Robert, Dillon, Richard, Levine, Max F., Leongamornlert, Daniel, Butler, Adam, Ganser, Arnold, Bullinger, Lars, Döhner, Konstanze, Ottmann, Oliver, Adams, Richard, Döhner, Hartmut, Campbell, Peter J., Burnett, Alan K., Dennis, Michael, Russell, Nigel H., Devlin, Sean M., Huntly, Brian J. P. and Papaemmanuil, Elli 2022. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature Communications 13 (1) , 4622. 10.1038/s41467-022-32103-8
file

Russell, Nigel H., Hills, Robert K., Thomas, Abin, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E. and Burnett, Alan K. 2022. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 (7) , pp. 1518-1527. 10.3324/haematol.2021.279010
file

Russell, Nigel H., Hills, Robert K., Kjeldsen, Lars, Clark, Richard E., Ali, Sahra, Cahalin, Paul, Thomas, Ian F. and Burnett, Alan K. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 10.1111/bjh.18195
Item availability restricted.
file

Coats, Thomas, Bean, Daniel, Basset, Aymeric, Sirkis, Tamir, Brammeld, Jonathan, Johnson, Sean, Thomas, Ian, Gilkes, Amanda, Raj, Kavita, Dennis, Mike, Knapper, Steven, Mehta, Priyanka, Khwaja, Asim, Hunter, Hannah, Tauro, Sudhir, Bowen, David, Jones, Gail, Dobson, Richard, Russell, Nigel and Dillon, Richard 2022. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology 196 (6) , pp. 1337-1343. 10.1111/bjh.18013
file

Stimpson, Madeleine L., Wolf, Julia S., Williams, Emily L., Lait, Philippa J. P., Schewitz?Bowers, Lauren P., Greenwood, Rosemary, Pell, Julie, Thomas, Ian, Lee, Richard W. J. and Bradbury, Charlotte A. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196 (4) , pp. 1113-1117. 10.1111/bjh.17884
Item availability restricted.
filefile

Dennis, Mike, Thomas, Ian F., Ariti, Cono, Upton, Laura, Burnett, Alan K., Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven, Clark, Richard E., Copland, Mhairi, Russell, Nigel and Hills, Robert K. 2021. Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances 5 (24) , pp. 5621-5625. 10.1182/bloodadvances.2021005038
file

Bradbury, Charlotte A., Pell, Julie, Hill, Quentin, Bagot, Catherine, Cooper, Nichola, Ingram, Jenny, Breheny, Katie, Kandiyali, Rebecca, Rayment, Rachel, Evans, Gillian, Talks, Kate, Thomas, Ian and Greenwood, Rosemary 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385 (10) , pp. 885-895. 10.1056/NEJMoa2100596

Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono, Severinsen, Marianne, Hemmaway, Claire, Greaves, Paul, Clark, Richard, Copland, Mhairi and Russell, Nigel 2021. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. British Journal of Haematology 194 (2) , pp. 298-308. 10.1111/bjh.17501

Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan and Spearing, Ruth 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8) , pp. 890-901. 10.1200/JCO.20.01170
file

Greenwood, Rosemary, Pell, Julie, Foscarini-Craggs, Paula, Wale, Katharine, Thomas, Ian and Bradbury, Charlotte 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21 (1) , 873. 10.1186/s13063-020-04798-x
file

Burnett, Alan K., Hills, R K, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32 , pp. 2693-2714. 10.1038/s41375-018-0148-3
file

Freeman, Sylvie D., Hills, Robert K., Virgo, Paul, Khan, Naeem, Couzens, Steve, Dillon, Richard, Gilkes, Amanda, Upton, Laura, Nielsen, Ove Juul, Cavenagh, James D., Jones, Gail, Khwaja, Asim, Cahalin, Paul, Thomas, Ian, Grimwade, Davied, Burnett, Alan K. and Russell, Nigel H. 2018. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. Journal of Clinical Oncology 36 (14) , pp. 1486-1497. 10.1200/JCO.2017.76.3425
file

Knapper, Steven, Russell, Nigel, Gilkes, Amanda, Hills, Robert K., Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648
file

Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian and Clark, Richard 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101 (6) , pp. 724-731. 10.3324/haematol.2016.141937
file

Burnett, A. K., Russell, N. H., Hills, Robert Kerrin, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-F., Cahalin, P., Dennis, M., Friis, L., Thomas, Ian, Milligan, D. and Clark, R. E. 2015. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood 125 (25) , pp. 3878-3885. 10.1182/blood-2015-01-623447

Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170 (1) , pp. 80-84. 10.1111/bjh.13398

Dennis, M., Russell, N., Hills, Robert Kerrin, Hemmaway, C., Panoskaltsis, N., McMullin, M. F., Kjeldsen, L., Dignum, H., Thomas, Ian, Clark, R. E., Milligan, D. and Burnett, Alan 2015. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood 125 (19) , pp. 2923-2932. 10.1182/blood-2014-10-608117

This list was generated on Thu Oct 6 04:17:00 2022 BST.